-
1
-
-
84875804295
-
Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
-
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49(6):1374-403
-
(2013)
Eur J Cancer
, vol.49
, Issue.6
, pp. 1374-1403
-
-
Ferlay, J.1
Steliarova-Foucher, E.2
Lortet-Tieulent, J.3
-
2
-
-
77954340426
-
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
-
Colombo N, Peiretti M, Parma G, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl 5):v23-30
-
(2010)
Ann Oncol
, vol.21
, Issue.SUPPL. 5
-
-
Colombo, N.1
Peiretti, M.2
Parma, G.3
-
4
-
-
0037440317
-
International collaborative ovarian neoplasm trial 1: A randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer
-
Colombo N, Guthrie D, Chiari S, et al. International collaborative ovarian neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst 2003;95(2):125-32
-
(2003)
J Natl Cancer Inst
, vol.95
, Issue.2
, pp. 125-132
-
-
Colombo, N.1
Guthrie, D.2
Chiari, S.3
-
5
-
-
0037440295
-
Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European organisation for research and treatment of cancer-adjuvant chemotherapy in ovarian neoplasm trial
-
Trimbos JB, Vergote I, Bolis G, et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European organisation for research and treatment of cancer-adjuvant chemotherapy in ovarian neoplasm trial. J Natl Cancer Inst 2003;95(2):113-25
-
(2003)
J Natl Cancer Inst
, vol.95
, Issue.2
, pp. 113-125
-
-
Trimbos, J.B.1
Vergote, I.2
Bolis, G.3
-
6
-
-
0141688377
-
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study
-
Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21(17):3194-200
-
(2003)
J Clin Oncol
, vol.21
, Issue.17
, pp. 3194-3200
-
-
Ozols, R.F.1
Bundy, B.N.2
Greer, B.E.3
-
7
-
-
9744223515
-
Phase III randomized trial of docetaxelcarboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma
-
Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxelcarboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004;96(22):1682-91
-
(2004)
J Natl Cancer Inst
, vol.96
, Issue.22
, pp. 1682-1691
-
-
Vasey, P.A.1
Jayson, G.C.2
Gordon, A.3
-
8
-
-
0026018186
-
Responses to second-line cisplatinbased intraperitoneal therapy in ovarian cancer: Influence of a prior response to intravenous cisplatin
-
Markman M, Reichman B, Hakes T, et al. Responses to second-line cisplatinbased intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J Clin Oncol 1991;9(10):1801-5
-
(1991)
J Clin Oncol
, vol.9
, Issue.10
, pp. 1801-1805
-
-
Markman, M.1
Reichman, B.2
Hakes, T.3
-
9
-
-
84875036495
-
Palliative systemic therapy for women with recurrent epithelial ovarian cancer: Current options
-
Elit L, Hirte H. Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options. Onco Targets Ther 2013;6:107-18
-
(2013)
Onco Targets Ther
, vol.6
, pp. 107-118
-
-
Elit, L.1
Hirte, H.2
-
10
-
-
0027131189
-
Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes
-
Vaage J, Donovan D, Mayhew E, et al. Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes. Cancer 1993;72(12):3671-5
-
(1993)
Cancer
, vol.72
, Issue.12
, pp. 3671-3675
-
-
Vaage, J.1
Donovan, D.2
Mayhew, E.3
-
11
-
-
18144379214
-
Correlation of epidermal growth factor receptor expression with tumor microdensity vessels and with vascular endothelial growth factor expression in ovarian carcinoma
-
Raspollini MR, Castiglione F, Garbini F, et al. Correlation of epidermal growth factor receptor expression with tumor microdensity vessels and with vascular endothelial growth factor expression in ovarian carcinoma. Int J Surg Pathol 2005;13(2):135-42
-
(2005)
Int J Surg Pathol
, vol.13
, Issue.2
, pp. 135-142
-
-
Raspollini, M.R.1
Castiglione, F.2
Garbini, F.3
-
12
-
-
84855425106
-
Incorporation of bevacizumab in the primary treatment of ovarian cancer
-
Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;365(26):2473-83
-
(2011)
N Engl J Med
, vol.365
, Issue.26
, pp. 2473-2483
-
-
Burger, R.A.1
Brady, M.F.2
Bookman, M.A.3
-
13
-
-
84855466019
-
A phase 3 trial of bevacizumab in ovarian cancer
-
Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365(26):2484-96
-
(2011)
N Engl J Med
, vol.365
, Issue.26
, pp. 2484-2496
-
-
Perren, T.J.1
Swart, A.M.2
Pfisterer, J.3
-
14
-
-
0036173892
-
Heterogeneity of ovarian cancer: Relationships among histological group, stage of disease, tumor markers, patient characteristics, and survival
-
Pieretti M, Hopenhayn-Rich C, Khattar NH, et al. Heterogeneity of ovarian cancer: relationships among histological group, stage of disease, tumor markers, patient characteristics, and survival. Cancer Invest 2002;20(1):11-23
-
(2002)
Cancer Invest
, vol.20
, Issue.1
, pp. 11-23
-
-
Pieretti, M.1
Hopenhayn-Rich, C.2
Khattar, N.H.3
-
15
-
-
0034332322
-
The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma
-
Shahin MS, Hughes JH, Sood AK, Buller RE. The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma. Cancer 2000;89(9):2006-17
-
(2000)
Cancer
, vol.89
, Issue.9
, pp. 2006-2017
-
-
Shahin, M.S.1
Hughes, J.H.2
Sood, A.K.3
Buller, R.E.4
-
16
-
-
84863599600
-
HER2 expression in ovarian carcinoma: Caution and complexity in biomarker analysis
-
author reply 71-2
-
McCaughan H, Um I, Langdon SP, et al. HER2 expression in ovarian carcinoma: caution and complexity in biomarker analysis. J Clin Pathol 2012;65(7):670-1; author reply 71-2
-
(2012)
J Clin Pathol
, vol.65
, Issue.7
, pp. 670-671
-
-
McCaughan, H.1
Um, I.2
Langdon, S.P.3
-
17
-
-
84873844780
-
Staining of MUC1 in ovarian cancer tissues with PankoMab-GEX detecting the tumour-associated epitope, TAMUC1, as compared to antibodies HMFG-1 and 115D8
-
Dian D, Lenhard M, Mayr D, et al. Staining of MUC1 in ovarian cancer tissues with PankoMab-GEX detecting the tumour-associated epitope, TAMUC1, as compared to antibodies HMFG-1 and 115D8. Histol Histopathol 2013;28(2):239-44
-
(2013)
Histol Histopathol
, vol.28
, Issue.2
, pp. 239-244
-
-
Dian, D.1
Lenhard, M.2
Mayr, D.3
-
18
-
-
0028063239
-
Isolation and characterization of CD47 glycoprotein: A multispanning membrane protein which is the same as integrin-associated protein (IAP) and the ovarian tumour marker OA3
-
Mawby WJ, Holmes CH, Anstee DJ, et al. Isolation and characterization of CD47 glycoprotein: a multispanning membrane protein which is the same as integrin-associated protein (IAP) and the ovarian tumour marker OA3. Biochem J 1994;304(Pt 2):525-30
-
(1994)
Biochem J
, vol.304
, Issue.PART 2
, pp. 525-530
-
-
Mawby, W.J.1
Holmes, C.H.2
Anstee, D.J.3
-
19
-
-
0032484540
-
Role of folate receptor and reduced folate carrier in the transport of 5- methyltetrahydrofolic acid in human ovarian carcinoma cells
-
Corona G, Giannini F, Fabris M, et al. Role of folate receptor and reduced folate carrier in the transport of 5- methyltetrahydrofolic acid in human ovarian carcinoma cells. Int J Cancer 1998;75(1):125-33
-
(1998)
Int J Cancer
, vol.75
, Issue.1
, pp. 125-133
-
-
Corona, G.1
Giannini, F.2
Fabris, M.3
-
20
-
-
34247618735
-
Expression of TAG-72 in ovarian cancer and its correlation with tumor stage and patient prognosis
-
Ponnusamy MP, Venkatraman G, Singh AP, et al. Expression of TAG-72 in ovarian cancer and its correlation with tumor stage and patient prognosis. Cancer Lett 2007;251(2):247-57
-
(2007)
Cancer Lett
, vol.251
, Issue.2
, pp. 247-257
-
-
Ponnusamy, M.P.1
Venkatraman, G.2
Singh, A.P.3
-
21
-
-
23844542990
-
Localization of mesothelin in epithelial ovarian cancer
-
Hassan R, Kreitman RJ, Pastan I, Willingham MC. Localization of mesothelin in epithelial ovarian cancer. Appl Immunohistochem Mol Morphol 2005;13(3):243-7
-
(2005)
Appl Immunohistochem Mol Morphol
, vol.13
, Issue.3
, pp. 243-247
-
-
Hassan, R.1
Kreitman, R.J.2
Pastan, I.3
Willingham, M.C.4
-
22
-
-
0348223937
-
Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms
-
Yakirevich E, Sabo E, Lavie O, et al. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms. Clin Cancer Res 2003;9(17):6453-60
-
(2003)
Clin Cancer Res
, vol.9
, Issue.17
, pp. 6453-6460
-
-
Yakirevich, E.1
Sabo, E.2
Lavie, O.3
-
23
-
-
0034630731
-
An Oacetylated sialyl-Tn is involved in ovarian cancer-associated antigenicity
-
Toba S, Tenno M, Kurosaka A. An Oacetylated sialyl-Tn is involved in ovarian cancer-associated antigenicity. Biochem Biophys Res Commun 2000;271(2):281-6
-
(2000)
Biochem Biophys Res Commun
, vol.271
, Issue.2
, pp. 281-286
-
-
Toba, S.1
Tenno, M.2
Kurosaka, A.3
-
24
-
-
77949429770
-
Ovarian cancer immunotherapy: Opportunities, progresses and challenges
-
Liu B, Nash J, Runowicz C, et al. Ovarian cancer immunotherapy: opportunities, progresses and challenges. J Hematol Oncol 2010;3:7
-
(2010)
J Hematol Oncol
, vol.3
, pp. 7
-
-
Liu, B.1
Nash, J.2
Runowicz, C.3
-
26
-
-
33846444354
-
High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer
-
Piersma SJ, Jordanova ES, van Poelgeest MI, et al. High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res 2007;67(1):354-61
-
(2007)
Cancer Res
, vol.67
, Issue.1
, pp. 354-361
-
-
Piersma, S.J.1
Jordanova, E.S.2
Van Poelgeest, M.I.3
-
27
-
-
84870288924
-
Cancer immunoediting by the innate immune system in the absence of adaptive immunity
-
O'Sullivan T, Saddawi-Konefka R, Vermi W, et al. Cancer immunoediting by the innate immune system in the absence of adaptive immunity. J Exp Med 2012;209(10):1869-82
-
(2012)
J Exp Med
, vol.209
, Issue.10
, pp. 1869-1882
-
-
O'sullivan, T.1
Saddawi-Konefka, R.2
Vermi, W.3
-
28
-
-
34248193253
-
Immune surveillance of tumors
-
Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest 2007;117(5):1137-46
-
(2007)
J Clin Invest
, vol.117
, Issue.5
, pp. 1137-1146
-
-
Swann, J.B.1
Smyth, M.J.2
-
29
-
-
38749145575
-
Correlation of NK T-like CD3 +CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy
-
Bamias A, Koutsoukou V, Terpos E, et al. Correlation of NK T-like CD3 +CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy. Gynecol Oncol 2008;108(2):421-7
-
(2008)
Gynecol Oncol
, vol.108
, Issue.2
, pp. 421-427
-
-
Bamias, A.1
Koutsoukou, V.2
Terpos, E.3
-
30
-
-
0033991158
-
Escape of human solid tumors from T-cell recognition: Molecular mechanisms and functional significance
-
Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000;74:181-273
-
(2000)
Adv Immunol
, vol.74
, pp. 181-273
-
-
Marincola, F.M.1
Jaffee, E.M.2
Hicklin, D.J.3
Ferrone, S.4
-
31
-
-
0037126310
-
Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation
-
Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002;419(6908):734-8
-
(2002)
Nature
, vol.419
, Issue.6908
, pp. 734-738
-
-
Groh, V.1
Wu, J.2
Yee, C.3
Spies, T.4
-
32
-
-
0035874949
-
Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer
-
Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001;61(12):4766-72
-
(2001)
Cancer Res
, vol.61
, Issue.12
, pp. 4766-4772
-
-
Woo, E.Y.1
Chu, C.S.2
Goletz, T.J.3
-
33
-
-
18144392697
-
Tumour-infiltrating gamma/delta Tlymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma
-
Raspollini MR, Castiglione F, Rossi Degl'innocenti D, et al. Tumour-infiltrating gamma/delta Tlymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma. Ann Oncol 2005;16(4):590-6
-
(2005)
Ann Oncol
, vol.16
, Issue.4
, pp. 590-596
-
-
Raspollini, M.R.1
Castiglione, F.2
Rossi Degl'innocenti, D.3
-
34
-
-
9844256432
-
Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: Twenty-four-hour versus 7-day infusion
-
Edwards RP, Gooding W, Lembersky BC, et al. Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion. J Clin Oncol 1997;15(11):3399-407
-
(1997)
J Clin Oncol
, vol.15
, Issue.11
, pp. 3399-3407
-
-
Edwards, R.P.1
Gooding, W.2
Lembersky, B.C.3
-
35
-
-
71849090003
-
A phase II trial of intraperitoneal interleukin-2 in patients with platinumresistant or platinum-refractory ovarian cancer
-
Vlad AM, Budiu RA, Lenzner DE, et al. A phase II trial of intraperitoneal interleukin-2 in patients with platinumresistant or platinum-refractory ovarian cancer. Cancer Immunol Immunother 2010;59(2):293-301
-
(2010)
Cancer Immunol Immunother
, vol.59
, Issue.2
, pp. 293-301
-
-
Vlad, A.M.1
Budiu, R.A.2
Lenzner, D.E.3
-
36
-
-
0037388367
-
TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class Irestricted T cells specific for autologous tumor in late-stage ovarian cancer patients
-
Schlienger K, Chu CS, Woo EY, et al. TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class Irestricted T cells specific for autologous tumor in late-stage ovarian cancer patients. Clin Cancer Res 2003;9(4):1517-27
-
(2003)
Clin Cancer Res
, vol.9
, Issue.4
, pp. 1517-1527
-
-
Schlienger, K.1
Chu, C.S.2
Woo, E.Y.3
-
37
-
-
33644854425
-
Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer
-
Goodell V, Salazar LG, Urban N, et al. Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer. J Clin Oncol 2006;24(5):762-8
-
(2006)
J Clin Oncol
, vol.24
, Issue.5
, pp. 762-768
-
-
Goodell, V.1
Salazar, L.G.2
Urban, N.3
-
38
-
-
0032793847
-
Clonal expansion of T cells that are specific for autologous ovarian tumor among tumorinfiltrating T cells in humans
-
Hayashi K, Yonamine K, Masuko-Hongo K, et al. Clonal expansion of T cells that are specific for autologous ovarian tumor among tumorinfiltrating T cells in humans. Gynecol Oncol 1999;74(1):86-92
-
(1999)
Gynecol Oncol
, vol.74
, Issue.1
, pp. 86-92
-
-
Hayashi, K.1
Yonamine, K.2
Masuko-Hongo, K.3
-
39
-
-
0027528759
-
Restricted T cell receptor V-beta and J-beta usage in T cells from interleukin-2-cultured lymphocytes of ovarian and renal carcinomas
-
Halapi E, Yamamoto Y, Juhlin C, et al. Restricted T cell receptor V-beta and J-beta usage in T cells from interleukin-2-cultured lymphocytes of ovarian and renal carcinomas. Cancer Immunol Immunother 1993;36(3):191-7
-
(1993)
Cancer Immunol Immunother
, vol.36
, Issue.3
, pp. 191-197
-
-
Halapi, E.1
Yamamoto, Y.2
Juhlin, C.3
-
40
-
-
0029053749
-
Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines
-
Fisk B, Blevins TL, Wharton JT, Ioannides CG. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 1995;181(6):2109-17
-
(1995)
J Exp Med
, vol.181
, Issue.6
, pp. 2109-2117
-
-
Fisk, B.1
Blevins, T.L.2
Wharton, J.T.3
Ioannides, C.G.4
-
41
-
-
0027787511
-
Cytokine production by T-cell lines derived from tumor-infiltrating lymphocytes from patients with ovarian carcinoma: Tumor-specific immune responses and inhibition of antigenindependent cytokine production by ovarian tumor cells
-
Kooi S, Freedman RS, Rodriguez-Villanueva J, Platsoucas CD. Cytokine production by T-cell lines derived from tumor-infiltrating lymphocytes from patients with ovarian carcinoma: tumor-specific immune responses and inhibition of antigenindependent cytokine production by ovarian tumor cells. Lymphokine Cytokine Res 1993;12(6):429-37
-
(1993)
Lymphokine Cytokine Res
, vol.12
, Issue.6
, pp. 429-437
-
-
Kooi, S.1
Freedman, R.S.2
Rodriguez-Villanueva, J.3
Platsoucas, C.D.4
-
42
-
-
0031672721
-
Ovarian cancer-associated lymphocyte recognition of folate binding protein peptides
-
Peoples GE, Anderson BW, Fisk B, et al. Ovarian cancer-associated lymphocyte recognition of folate binding protein peptides. Ann Surg Oncol 1998;5(8):743-50
-
(1998)
Ann Surg Oncol
, vol.5
, Issue.8
, pp. 743-750
-
-
Peoples, G.E.1
Anderson, B.W.2
Fisk, B.3
-
43
-
-
0000052318
-
Tumor-infiltrating lymphocytes from human ovarian cancer patients recognize autologous tumor in an MHC class II-restricted fashion
-
Dadmarz RD, Ordoubadi A, Mixon A, et al. Tumor-infiltrating lymphocytes from human ovarian cancer patients recognize autologous tumor in an MHC class II-restricted fashion. Cancer J Sci Am 1996;2(5):263-72
-
(1996)
Cancer J Sci Am
, vol.2
, Issue.5
, pp. 263-272
-
-
Dadmarz, R.D.1
Ordoubadi, A.2
Mixon, A.3
-
44
-
-
0034734986
-
Induction of ovarian tumor-specific CD8 + cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells
-
Santin AD, Bellone S, Ravaggi A, et al. Induction of ovarian tumor-specific CD8 + cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells. Obstet Gynecol 2000;96(3):422-30
-
(2000)
Obstet Gynecol
, vol.96
, Issue.3
, pp. 422-430
-
-
Santin, A.D.1
Bellone, S.2
Ravaggi, A.3
-
45
-
-
0027265296
-
T-cell recognition of ovarian cancer
-
Peoples GE, Schoof DD, Andrews JV, et al. T-cell recognition of ovarian cancer. Surgery 1993;114(2):227-34
-
(1993)
Surgery
, vol.114
, Issue.2
, pp. 227-234
-
-
Peoples, G.E.1
Schoof, D.D.2
Andrews, J.V.3
-
46
-
-
0037448353
-
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer
-
Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348(3):203-13
-
(2003)
N Engl J Med
, vol.348
, Issue.3
, pp. 203-213
-
-
Zhang, L.1
Conejo-Garcia, J.R.2
Katsaros, D.3
-
47
-
-
67649624673
-
Intraepithelial T cells and tumor proliferation: Impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer
-
Adams SF, Levine DA, Cadungog MG, et al. Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer. Cancer 2009;115(13):2891-902
-
(2009)
Cancer
, vol.115
, Issue.13
, pp. 2891-2902
-
-
Adams, S.F.1
Levine, D.A.2
Cadungog, M.G.3
-
48
-
-
29444442811
-
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
-
Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005;102(51):18538-43
-
(2005)
Proc Natl Acad Sci U S A
, vol.102
, Issue.51
, pp. 18538-18543
-
-
Sato, E.1
Olson, S.H.2
Ahn, J.3
-
49
-
-
58149303099
-
Prognostic significance of tumorinfiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer
-
Leffers N, Gooden MJ, de Jong RA, et al. Prognostic significance of tumorinfiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother 2009;58(3):449-59
-
(2009)
Cancer Immunol Immunother
, vol.58
, Issue.3
, pp. 449-459
-
-
Leffers, N.1
Gooden, M.J.2
De Jong, R.A.3
-
50
-
-
68149141666
-
Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors
-
Milne K, Kobel M, Kalloger SE, et al. Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS ONE 2009;4(7):e6412
-
(2009)
PLoS ONE
, vol.4
, Issue.7
-
-
Milne, K.1
Kobel, M.2
Kalloger, S.E.3
-
51
-
-
69849107597
-
Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments
-
Kryczek I, Banerjee M, Cheng P, et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 2009;114(6):1141-9
-
(2009)
Blood
, vol.114
, Issue.6
, pp. 1141-1149
-
-
Kryczek, I.1
Banerjee, M.2
Cheng, P.3
-
52
-
-
0027414895
-
Natural killer cell activity and progression-free survival in ovarian cancer
-
Garzetti GG, Cignitti M, Ciavattini A, et al. Natural killer cell activity and progression-free survival in ovarian cancer. Gynecol Obstet Invest 1993;35(2):118-20
-
(1993)
Gynecol Obstet Invest
, vol.35
, Issue.2
, pp. 118-120
-
-
Garzetti, G.G.1
Cignitti, M.2
Ciavattini, A.3
-
53
-
-
33644652161
-
NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma
-
Dong HP, Elstrand MB, Holth A, et al. NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma. Am J Clin Pathol 2006;125(3):451-8
-
(2006)
Am J Clin Pathol
, vol.125
, Issue.3
, pp. 451-458
-
-
Dong, H.P.1
Elstrand, M.B.2
Holth, A.3
-
54
-
-
33749016477
-
T-cell immunity to the folate receptor alpha is prevalent in women with breast or ovarian cancer
-
Knutson KL, Krco CJ, Erskine CL, et al. T-cell immunity to the folate receptor alpha is prevalent in women with breast or ovarian cancer. J Clin Oncol 2006;24(26):4254-61
-
(2006)
J Clin Oncol
, vol.24
, Issue.26
, pp. 4254-4261
-
-
Knutson, K.L.1
Krco, C.J.2
Erskine, C.L.3
-
55
-
-
74749105337
-
Expression and serum immunoreactivity of developmentally restricted differentiation antigens in epithelial ovarian cancer
-
Tchabo NE, Mhawech-Fauceglia P, Caballero OL, et al. Expression and serum immunoreactivity of developmentally restricted differentiation antigens in epithelial ovarian cancer. Cancer Immun 2009;9:6
-
(2009)
Cancer Immun
, vol.9
, pp. 6
-
-
Tchabo, N.E.1
Mhawech-Fauceglia, P.2
Caballero, O.L.3
-
56
-
-
65249173447
-
Adoptive cell therapy for the treatment of patients with metastatic melanoma
-
Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 2009;21(2):233-40
-
(2009)
Curr Opin Immunol
, vol.21
, Issue.2
, pp. 233-240
-
-
Rosenberg, S.A.1
Dudley, M.E.2
-
58
-
-
0037364804
-
Natural versus adaptive regulatory T cells
-
Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol 2003;3(3):253-7
-
(2003)
Nat Rev Immunol
, vol.3
, Issue.3
, pp. 253-257
-
-
Bluestone, J.A.1
Abbas, A.K.2
-
59
-
-
33646371011
-
Foxp3 expressing CD4+ CD25+ and CD8+CD28- T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma
-
Meloni F, Morosini M, Solari N, et al. Foxp3 expressing CD4+ CD25+ and CD8+CD28- T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma. Hum Immunol 2006;67(1-2):1-12
-
(2006)
Hum Immunol
, vol.67
, Issue.1-2
, pp. 1-12
-
-
Meloni, F.1
Morosini, M.2
Solari, N.3
-
60
-
-
36049009999
-
Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: A Phase i clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes
-
Audia S, Nicolas A, Cathelin D, et al. Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes. Clin Exp Immunol 2007;150(3):523-30
-
(2007)
Clin Exp Immunol
, vol.150
, Issue.3
, pp. 523-530
-
-
Audia, S.1
Nicolas, A.2
Cathelin, D.3
-
61
-
-
24944519910
-
Proportion of CD4+CD25+ regulatory T cell is increased in the patients with ovarian carcinoma
-
Li X, Ye DF, Xie X, et al. Proportion of CD4+CD25+ regulatory T cell is increased in the patients with ovarian carcinoma. Cancer Invest 2005;23(5):399-403
-
(2005)
Cancer Invest
, vol.23
, Issue.5
, pp. 399-403
-
-
Li, X.1
Ye, D.F.2
Xie, X.3
-
62
-
-
4644237613
-
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
-
Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10(9):942-9
-
(2004)
Nat Med
, vol.10
, Issue.9
, pp. 942-949
-
-
Curiel, T.J.1
Coukos, G.2
Zou, L.3
-
63
-
-
28544433483
-
The expression of the regulatory T cellspecific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer
-
Wolf D, Wolf AM, Rumpold H, et al. The expression of the regulatory T cellspecific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 2005;11(23):8326-31
-
(2005)
Clin Cancer Res
, vol.11
, Issue.23
, pp. 8326-8331
-
-
Wolf, D.1
Wolf, A.M.2
Rumpold, H.3
-
64
-
-
85026139580
-
Ovarian cancer cells induce peripheral mature dendritic cells to differentiate into macrophagelike cells in vitro
-
Chen F, Hou M, Ye F, et al. Ovarian cancer cells induce peripheral mature dendritic cells to differentiate into macrophagelike cells in vitro. Int J Gynecol Cancer 2009;19(9):1487-93
-
(2009)
Int J Gynecol Cancer
, vol.19
, Issue.9
, pp. 1487-1493
-
-
Chen, F.1
Hou, M.2
Ye, F.3
-
65
-
-
43249095919
-
Tumor angiogenesis
-
Kerbel RS. Tumor angiogenesis. N Engl J Med 2008;358(19):2039-49
-
(2008)
N Engl J Med
, vol.358
, Issue.19
, pp. 2039-2049
-
-
Kerbel, R.S.1
-
66
-
-
77953487609
-
Myeloid cells in the tumor microenvironment: Modulation of tumor angiogenesis and tumor inflammation
-
Schmid MC, Varner JA. Myeloid cells in the tumor microenvironment: modulation of tumor angiogenesis and tumor inflammation. J Oncol 2010;2010:201026
-
(2010)
J Oncol
, vol.2010
, pp. 201026
-
-
Schmid, M.C.1
Varner, J.A.2
-
67
-
-
77955549860
-
Myeloid-derived suppressor cells: More mechanisms for inhibiting antitumor immunity
-
Ostrand-Rosenberg S. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother 2010;59(10):1593-600
-
(2010)
Cancer Immunol Immunother
, vol.59
, Issue.10
, pp. 1593-1600
-
-
Ostrand-Rosenberg, S.1
-
68
-
-
33847611968
-
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer
-
Hamanishi J, Mandai M, Iwasaki M, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA 2007;104(9):3360-5
-
(2007)
Proc Natl Acad Sci USA
, vol.104
, Issue.9
, pp. 3360-3365
-
-
Hamanishi, J.1
Mandai, M.2
Iwasaki, M.3
-
69
-
-
33646367200
-
The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: Correlation with important high-risk prognostic factors
-
Ghebeh H, Mohammed S, Al-Omair A, et al. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 2006;8(3):190-8
-
(2006)
Neoplasia
, vol.8
, Issue.3
, pp. 190-198
-
-
Ghebeh, H.1
Mohammed, S.2
Al-Omair, A.3
-
70
-
-
70350247885
-
Tumor-expressed B7-H1 and B7- DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma
-
Karim R, Jordanova ES, Piersma SJ, et al. Tumor-expressed B7-H1 and B7- DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma. Clin Cancer Res 2009;15(20):6341-7
-
(2009)
Clin Cancer Res
, vol.15
, Issue.20
, pp. 6341-6347
-
-
Karim, R.1
Jordanova, E.S.2
Piersma, S.J.3
-
71
-
-
70349234325
-
B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders
-
Wilcox RA, Feldman AL, Wada DA, et al. B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood 2009;114(10):2149-58
-
(2009)
Blood
, vol.114
, Issue.10
, pp. 2149-2158
-
-
Wilcox, R.A.1
Feldman, A.L.2
Wada, D.A.3
-
72
-
-
54749135372
-
Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity
-
Huarte E, Cubillos-Ruiz JR, Nesbeth YC, et al. Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity. Cancer Res 2008;68(18):7684-91
-
(2008)
Cancer Res
, vol.68
, Issue.18
, pp. 7684-7691
-
-
Huarte, E.1
Cubillos-Ruiz, J.R.2
Nesbeth, Y.C.3
-
73
-
-
48749116913
-
Ovarian cancer cells modulate human blood neutrophils response to activation in vitro
-
Klink M, Jastrzembska K, Nowak M, et al. Ovarian cancer cells modulate human blood neutrophils response to activation in vitro. Scand J Immunol 2008;68(3):328-36
-
(2008)
Scand J Immunol
, vol.68
, Issue.3
, pp. 328-336
-
-
Klink, M.1
Jastrzembska, K.2
Nowak, M.3
-
74
-
-
77955862760
-
Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer
-
An X, Ding PR, Li YH, et al. Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer. Biomarkers 2010;15(6):516-22
-
(2010)
Biomarkers
, vol.15
, Issue.6
, pp. 516-522
-
-
An, X.1
Ding, P.R.2
Li, Y.H.3
-
75
-
-
54849431185
-
Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment
-
Cho H, Hur HW, Kim SW, et al. Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother 2009;58(1):15-23
-
(2009)
Cancer Immunol Immunother
, vol.58
, Issue.1
, pp. 15-23
-
-
Cho, H.1
Hur, H.W.2
Kim, S.W.3
-
76
-
-
78149406896
-
Elevated preoperative neutrophil to lymphocyte ratio predicts risk of recurrence following curative resection for stage IIA colon cancer
-
Ding PR, An X, Zhang RX, et al. Elevated preoperative neutrophil to lymphocyte ratio predicts risk of recurrence following curative resection for stage IIA colon cancer. Int J Colorectal Dis 2010;25(12):1427-33
-
(2010)
Int J Colorectal Dis
, vol.25
, Issue.12
, pp. 1427-1433
-
-
Ding, P.R.1
An, X.2
Zhang, R.X.3
-
77
-
-
77953912251
-
Neutrophil to lymphocyte ratio for preoperative diagnosis of uterine sarcomas: A case-matched comparison
-
Kim HS, Han KH, Chung HH, et al. Neutrophil to lymphocyte ratio for preoperative diagnosis of uterine sarcomas: a case-matched comparison. Eur J Surg Oncol 2010;36(7):691-8
-
(2010)
Eur J Surg Oncol
, vol.36
, Issue.7
, pp. 691-698
-
-
Kim, H.S.1
Han, K.H.2
Chung, H.H.3
-
78
-
-
77957932514
-
High preoperative neutrophillymphocyte ratio predicts poor survival in patients with gastric cancer
-
Shimada H, Takiguchi N, Kainuma O, et al. High preoperative neutrophillymphocyte ratio predicts poor survival in patients with gastric cancer. Gastric Cancer 2010;13(3):170-6
-
(2010)
Gastric Cancer
, vol.13
, Issue.3
, pp. 170-176
-
-
Shimada, H.1
Takiguchi, N.2
Kainuma, O.3
-
79
-
-
84864518399
-
A phase i clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer
-
Kandalaft LE, Powell DJ, Coukos G. A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer. J Transl Med 2012;10:157
-
(2012)
J Transl Med
, vol.10
, pp. 157
-
-
Kandalaft, L.E.1
Powell, D.J.2
Coukos, G.3
-
80
-
-
84874625308
-
Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo costimulated T cells in recurrent ovarian cancer
-
Kandalaft LE, Powell DJ, Chiang CL, et al. Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo costimulated T cells in recurrent ovarian cancer. Oncoimmunology 2013;2(1):e22664
-
(2013)
Oncoimmunology
, vol.2
, Issue.1
-
-
Kandalaft, L.E.1
Powell, D.J.2
Chiang, C.L.3
-
81
-
-
73949118563
-
Maintenance immunotherapy in recurrent ovarian cancer: Long term follow-up of a phase II study
-
Recchia F, Di Orio F, Candeloro G, et al. Maintenance immunotherapy in recurrent ovarian cancer: long term follow-up of a phase II study. Gynecol Oncol 2010;116(2):202-7
-
(2010)
Gynecol Oncol
, vol.116
, Issue.2
, pp. 202-207
-
-
Recchia, F.1
Di Orio, F.2
Candeloro, G.3
-
82
-
-
78650400901
-
A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer
-
Geller MA, Cooley S, Judson PL, et al. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 2011;13(1):98-107
-
(2011)
Cytotherapy
, vol.13
, Issue.1
, pp. 98-107
-
-
Geller, M.A.1
Cooley, S.2
Judson, P.L.3
-
83
-
-
84862330575
-
Immunotherapy with IL-10- and IFN-g-producing CD4 effector cells modulate "Natural" and "Inducible" CD4 TReg cell subpopulation levels: Observations in four cases of patients with ovarian cancer
-
Dobrzanski MJ, Rewers-Felkins KA, Samad KA, et al. Immunotherapy with IL-10- and IFN-g-producing CD4 effector cells modulate "Natural" and "Inducible" CD4 TReg cell subpopulation levels: observations in four cases of patients with ovarian cancer. Cancer Immunol Immunother 2012;61(6):839-54
-
(2012)
Cancer Immunol Immunother
, vol.61
, Issue.6
, pp. 839-854
-
-
Dobrzanski, M.J.1
Rewers-Felkins, K.A.2
Samad, K.A.3
-
84
-
-
84856834217
-
Cytotoxic Tlymphocyte immunotherapy for ovarian cancer: A pilot study
-
Wright SE, Rewers-Felkins KA, Quinlin IS, et al. Cytotoxic Tlymphocyte immunotherapy for ovarian cancer: a pilot study. J Immunother 2012;35(2):196-204
-
(2012)
J Immunother
, vol.35
, Issue.2
, pp. 196-204
-
-
Wright, S.E.1
Rewers-Felkins, K.A.2
Quinlin, I.S.3
-
85
-
-
34447132202
-
Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti- CD3 antibody: A phase I/II study
-
Burges A, Wimberger P, Kumper C, et al. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti- CD3 antibody: a phase I/II study. Clin Cancer Res 2007;13(13):3899-905
-
(2007)
Clin Cancer Res
, vol.13
, Issue.13
, pp. 3899-3905
-
-
Burges, A.1
Wimberger, P.2
Kumper, C.3
-
86
-
-
77954676136
-
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial
-
Heiss MM, Murawa P, Koralewski P, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer 2010;127(9):2209-21
-
(2010)
Int J Cancer
, vol.127
, Issue.9
, pp. 2209-2221
-
-
Heiss, M.M.1
Murawa, P.2
Koralewski, P.3
-
87
-
-
0009881031
-
Speculations on idiotypes and homobodies
-
Lindenmann J. Speculations on idiotypes and homobodies. Ann Immunol (Paris) 1973;124(2):171-84
-
(1973)
Ann Immunol (Paris)
, vol.124
, Issue.2
, pp. 171-184
-
-
Lindenmann, J.1
-
88
-
-
0015956495
-
Towards a network theory of the immune system
-
Jerne NK. Towards a network theory of the immune system. Ann Immunol (Paris) 1974;125C(1-2):373-89
-
(1974)
Ann Immunol (Paris)
, vol.125 C
, Issue.1-2
, pp. 373-389
-
-
Jerne, N.K.1
-
89
-
-
12144287745
-
Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: Immunological response and survival (phase Ib/II)
-
Reinartz S, Kohler S, Schlebusch H, et al. Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II). Clin Cancer Res 2004;10(5):1580-7
-
(2004)
Clin Cancer Res
, vol.10
, Issue.5
, pp. 1580-1587
-
-
Reinartz, S.1
Kohler, S.2
Schlebusch, H.3
-
90
-
-
79951743656
-
Abagovomab: An antiidiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer
-
Grisham RN, Berek J, Pfisterer J, Sabbatini P. Abagovomab: an antiidiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer. Immunotherapy 2011;3(2):153-62
-
(2011)
Immunotherapy
, vol.3
, Issue.2
, pp. 153-162
-
-
Grisham, R.N.1
Berek, J.2
Pfisterer, J.3
Sabbatini, P.4
-
91
-
-
84876529191
-
Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: A phase III trial of the AGO OVAR, COGI, GINECO, and GEICO - The MIMOSA study
-
Sabbatini P, Harter P, Scambia G, et al. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO - the MIMOSA study. J Clin Oncol 2013;31(12):1554-61
-
(2013)
J Clin Oncol
, vol.31
, Issue.12
, pp. 1554-1561
-
-
Sabbatini, P.1
Harter, P.2
Scambia, G.3
-
92
-
-
58549088720
-
Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer
-
Berek J, Taylor P, McGuire W, et al. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J Clin Oncol 2009;27(3):418-25
-
(2009)
J Clin Oncol
, vol.27
, Issue.3
, pp. 418-425
-
-
Berek, J.1
Taylor, P.2
McGuire, W.3
-
93
-
-
44949115169
-
CA125 velocity at relapse is a highly significant predictor of survival post relapse: Results of a 5-year follow-up survey to a randomized placebocontrolled study of maintenance oregovomab immunotherapy in advanced ovarian cancer
-
Berek JS, Taylor PT, Nicodemus CF. CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5-year follow-up survey to a randomized placebocontrolled study of maintenance oregovomab immunotherapy in advanced ovarian cancer. J Immunother 31(2):207-14
-
J Immunother
, vol.31
, Issue.2
, pp. 207-214
-
-
Berek, J.S.1
Taylor, P.T.2
Nicodemus, C.F.3
-
94
-
-
14244250598
-
A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer
-
Ehlen TG, Hoskins PJ, Miller D, et al. A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. Int J Gynecol Cancer 2005;15(6):1023-34
-
(2005)
Int J Gynecol Cancer
, vol.15
, Issue.6
, pp. 1023-1034
-
-
Ehlen, T.G.1
Hoskins, P.J.2
Miller, D.3
-
95
-
-
65549085361
-
The Immune adjuvant properties of front-line carboplatin-paclitaxel: A randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer
-
Braly P, Nicodemus CF, Chu C, et al. The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer. J Immunother 2009;32(1):54-65
-
(2009)
J Immunother
, vol.32
, Issue.1
, pp. 54-65
-
-
Braly, P.1
Nicodemus, C.F.2
Chu, C.3
-
96
-
-
84855662184
-
Anti-idiotypic single chain mimicking CA125 linked with tuftsin provides protective immunity against ovarian cancer in mice
-
Yuan W, Xia G, Zhao C, et al. Anti-idiotypic single chain mimicking CA125 linked with tuftsin provides protective immunity against ovarian cancer in mice. Mol Med Rep 2012;5(2):388-94
-
(2012)
Mol Med Rep
, vol.5
, Issue.2
, pp. 388-394
-
-
Yuan, W.1
Xia, G.2
Zhao, C.3
-
97
-
-
84867098819
-
The role of costimulatory molecules in directing the functional differentiation of alloreactive T helper cells
-
Magee CN, Boenisch O, Najafian N. The role of costimulatory molecules in directing the functional differentiation of alloreactive T helper cells. Am J Transplant 2012;12(10):2588-600
-
(2012)
Am J Transplant
, vol.12
, Issue.10
, pp. 2588-2600
-
-
Magee, C.N.1
Boenisch, O.2
Najafian, N.3
-
98
-
-
0344341626
-
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
-
Hodi FS, Mihm MC, Soiffer RJ, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 2003;100(8):4712-17
-
(2003)
Proc Natl Acad Sci USA
, vol.100
, Issue.8
, pp. 4712-4717
-
-
Hodi, F.S.1
Mihm, M.C.2
Soiffer, R.J.3
-
99
-
-
84879104519
-
Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors
-
Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G. Dual blockade of PD-1 and. CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res 2013;73(12):3591-603
-
(2013)
Cancer Res
, vol.73
, Issue.12
, pp. 3591-3603
-
-
Duraiswamy, J.1
Kaluza, K.M.2
Freeman, G.J.3
Coukos, G.4
|